DanshensuCAS# 76822-21-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 76822-21-4 | SDF | Download SDF |
| PubChem ID | 11600642 | Appearance | White crystal |
| Formula | C9H10O5 | M.Wt | 198.17 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Dan shen suan A; Salvianic acid A | ||
| Solubility | H2O : 6.2 mg/mL (31.29 mM; Need ultrasonic and warming) | ||
| Chemical Name | (2R)-3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid | ||
| SMILES | C1=CC(=C(C=C1CC(C(=O)O)O)O)O | ||
| Standard InChIKey | PAFLSMZLRSPALU-MRVPVSSYSA-N | ||
| Standard InChI | InChI=1S/C9H10O5/c10-6-2-1-5(3-7(6)11)4-8(12)9(13)14/h1-3,8,10-12H,4H2,(H,13,14)/t8-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Danshensu Dilution Calculator
Danshensu Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.0462 mL | 25.2309 mL | 50.4617 mL | 100.9234 mL | 126.1543 mL |
| 5 mM | 1.0092 mL | 5.0462 mL | 10.0923 mL | 20.1847 mL | 25.2309 mL |
| 10 mM | 0.5046 mL | 2.5231 mL | 5.0462 mL | 10.0923 mL | 12.6154 mL |
| 50 mM | 0.1009 mL | 0.5046 mL | 1.0092 mL | 2.0185 mL | 2.5231 mL |
| 100 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.0092 mL | 1.2615 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Danshensu, an active ingredient of Salvia miltiorrhiza, shows wide cardiovascular benefit by activating Nrf2 signaling pathway.
In Vitro:Danshensu (DSS) significantly decreases the level of the marker enzymes (creatine kinase and lactate dehydrogenase) from the coronary effluents and myocardial infarction size. This could markedly contribute to the recovery of cardiac function after I/R injury. DSS also has ROS scavenging activity and boosts endogenous antioxidants such as SOD, CAT, MDA, GSH-PX and HO-1 activities by activating nuclear factor erythroid-2-related factor 2 (Nrf2) signaling pathway which is mediated by Akt and ERK1/2 in western blot analysis[2].
In Vivo:Acute treatment with a single dose of danshensu in rats with normal tHcy does not change plasma tHcy. In contrast, danshensu significantly lowers tHcy in rats with elevated tHcy. The relatively higher cysteine and glutathione levels after treatment with danshensu indicates that its tHcy-lowering effect is via increased activity of the trans-sulphuration pathway[1].
References:
[1]. YG Cao, et al. Beneficial effects of danshensu, an active component of Salvia miltiorrhiza, on homocysteine metabolism via the trans-sulphuration pathway in rats. Br J Pharmacol. 2009 Jun; 157(3): 482–490.
[2]. Yu J, et al. Danshensu protects isolated heart against ischemia reperfusion injury through activation of Akt/ERK1/2/Nrf2 signaling. Int J Clin Exp Med. 2015 Sep 15;8(9):14793-804.
- Pimaricin
Catalog No.:BCN2216
CAS No.:7681-93-8
- Ronidazole
Catalog No.:BCC4840
CAS No.:7681-76-7
- Potassium Iodide
Catalog No.:BCC4826
CAS No.:7681-11-0
- Azathramycin
Catalog No.:BCC1392
CAS No.:76801-85-9
- 3-Hydroxy-4',5,7-trimethoxyflavanone
Catalog No.:BCN4316
CAS No.:76792-94-4
- 2'-Hydroxydaidzein
Catalog No.:BCN4585
CAS No.:7678-85-5
- GBR 12935
Catalog No.:BCC5381
CAS No.:76778-22-8
- Lupalbigenin
Catalog No.:BCN4314
CAS No.:76754-24-0
- Pyronaridine Tetraphosphate
Catalog No.:BCC1144
CAS No.:76748-86-2
- Decumbenine
Catalog No.:BCC8312
CAS No.:76733-83-0
- Mallorepine
Catalog No.:BCN4317
CAS No.:767-98-6
- 1-Deacetylnimbolinin B
Catalog No.:BCN4313
CAS No.:76689-98-0
- Famotidine
Catalog No.:BCC4529
CAS No.:76824-35-6
- 5-BDBD
Catalog No.:BCC7717
CAS No.:768404-03-1
- Przewaquinone A
Catalog No.:BCN3004
CAS No.:76843-23-7
- 6-Hydroxywogonin
Catalog No.:BCN6556
CAS No.:76844-70-7
- 8-Methyl-8-azabicyclo[3.2.1]octane-3,6-diol, 9CI; (3RS,6RS)-form, 3-O-Ac
Catalog No.:BCN1361
CAS No.:7688-76-8
- Olivil 4'-O-glucoside
Catalog No.:BCN7557
CAS No.:76880-93-8
- Camptothecin
Catalog No.:BCN4318
CAS No.:7689-03-4
- Bz-Gly-OH.HCl
Catalog No.:BCC2945
CAS No.:7689-50-1
- Triacsin C
Catalog No.:BCC7377
CAS No.:76896-80-5
- 13-Methyl-8,11,13-podocarpatriene-3,12-diol
Catalog No.:BCN1360
CAS No.:769140-74-1
- Begacestat
Catalog No.:BCC2346
CAS No.:769169-27-9
- Viscosalactone B
Catalog No.:BCN7945
CAS No.:76938-46-0
Multiple on-line screening and identification methods for hydroxyl radical scavengers in Yudanshen.[Pubmed:29730337]
J Pharm Biomed Anal. 2018 Jul 15;156:278-283.
Yudanshen, the genuine medicinal materials of Danshen (Salvia miltiorrhiza), is a well-known traditional Chinese medicine (TCM) used to treat cardiovascular and cerebrovascular diseases. Although its pharmacological and antioxidative activities have been well-documented, there is little research on the hydroxyl radical (OH) scavenging capacity of Yudanshen. In this study, we established multiple on-line high-performance liquid chromatography- chemiluminescence detector-diode-quadrupole-time of flight mass spectrometry (HPLC-CL-DAD-Q-TOF/MS) methods to rapidly screen and identify the OH scavengers in Yudanshen simultaneously. The chromatographic and potency fingerprints revealed seventeen peaks that showed the inhibition of OH. Fourteen of them were identified as Danshensu, protocatechuic aldehyde, caffeic acid, ferulic acid, salvianolic acid F, salvianolic acid H/L, salvianolic acid G, salvianolic acid D, salvianolic acid E, rosmarinic acid, salvianolic acid B, isosalvianolic acid B, salvianolic acid A, and salvianolic acid C. This study explores the OH scavenging activities of Yudanshen, and provides novel and powerful multiple on-line methods in the field of TCM for rapid screening and identification of OH scavengers.
Inhibitory effects of Danhong Injection and its major constituents on human cytochrome P450 enzymes in vitro.[Pubmed:29578591]
Biomed Chromatogr. 2018 Aug;32(8):e4250.
Danhong Injection (DHI) as a Chinese patent medicine is mainly used to treat ischemic encephalopathy and coronary heart disease in combination with other chemotherapy. However, the information on DHI's potential drug interactions is limited. The goal of this work was to examine the potential P450-mediated metabolism drug interaction arising from DHI and its active components. The results showed that DHI inhibited CYP2C19, CYP2D6, CYP3A4, CYP2E1 and CYP2C9 with IC50 values of 1.26, 1.42, 1.63, 1.10 and 1.67% (v/v), respectively. Danshensu and rosmarinic acid inhibited CYP2E1 and CYP2C9 with IC50 values of 36.63 and 75.76 mum, and 34.42 and 76.89 mum, respectively. Salvianolic acid A and B inhibited CYP2D6, CYP2E1 and CYP2C9 with IC50 values of 33.79, 21.64 and 31.94 mum, and 45.47, 13.52 and 24.15 mum, respectively. The study provides some useful information for safe and effective use of DHI in clinical practice.
Rapid Screening and Quantitative Determination of Active Components in Qing-Hua-Yu-Re-Formula Using UHPLC-Q-TOF/MS and HPLC-UV.[Pubmed:29713560]
J Anal Methods Chem. 2018 Mar 11;2018:8535127.
Qing-Hua-Yu-Re-Formula (QHYRF), a new herbal preparation, has been extensively used for treating diabetic cardiomyopathy. However, the chemical constituents of QHYRF remain uninvestigated. In the present study, rapid ultrahigh-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UHPLC-Q-TOF/MS) was used to qualitatively analyze the components of QHYRF. Qualitative detection was performed on a Kromasil C18 column through the gradient elution mode, using acetonitrile-water containing 0.1% formic acid. Twenty-seven compounds were identified or tentatively characterized, including 12 phenolic acids, nine monoterpene glycosides, two flavonoids, three iridoids, and one unknown compound. Among these, six compounds were confirmed by comparing with standards. A high-performance liquid chromatography (HPLC) method was developed to simultaneously determine the following six active components in QHYRF: Danshensu, paeoniflorin, acteoside, lithospermic acid, salvianolic acid B, and salvianolic acid C. These HPLC chromatograms were monitored at 254, 280, and 320 nm. The method was well validated with respect to specificity, linearity, limit of detection, limit of quantification, precision, stability, and recovery. The HPLC-UV method was successfully applied to 10 batches of QHYRF.
Salvia miltiorrhizaBurge (Danshen): a golden herbal medicine in cardiovascular therapeutics.[Pubmed:29698387]
Acta Pharmacol Sin. 2018 May;39(5):802-824.
Salvia miltiorrhiza Burge (Danshen) is an eminent medicinal herb that possesses broad cardiovascular and cerebrovascular protective actions and has been used in Asian countries for many centuries. Accumulating evidence suggests that Danshen and its components prevent vascular diseases, in particular, atherosclerosis and cardiac diseases, including myocardial infarction, myocardial ischemia/reperfusion injury, arrhythmia, cardiac hypertrophy and cardiac fibrosis. The published literature indicates that lipophilic constituents (tanshinone I, tanshinone IIa, tanshinone IIb, cryptotanshinone, dihydrotanshinone, etc) as well as hydrophilic constituents (Danshensu, salvianolic acid A and B, protocatechuic aldehyde, etc) contribute to the cardiovascular protective actions of Danshen, suggesting a potential synergism among these constituents. Herein, we provide a systematic up-to-date review on the cardiovascular actions and therapeutic potential of major pharmacologically active constituents of Danshen. These bioactive compounds will serve as excellent drug candidates in small-molecule cardiovascular drug discovery. This article also provides a scientific rationale for understanding the traditional use of Danshen in cardiovascular therapeutics.
Tanshinol borneol ester on nanostructured lipid carriers has longer brain and systemic effector retention and better antioxidant activity in vivo.[Pubmed:29695905]
Int J Nanomedicine. 2018 Apr 12;13:2265-2274.
Background: Tanshinol borneol ester (DBZ) is a hybrid of Danshensu (DSS) and borneol and has anti-ischemic activity in animals. However, its low water solubility and short half-life limit its clinical application. Methods: We prepared polyethylene glycol (PEG)-modified and DBZ-loaded nanostructured lipid carriers (DBZ-PEG-NLC) and DBZ-NLC, and examined their physical characteristics, such as particle size, zeta potential, entrapment efficiency and drug loading. The in vitro stability and pharmacokinetics in rats as well as antioxidant activity of DBZ-PEG-NLC and DBZ-NLC in a C57BL/6 mouse model of ischemia/reperfusion-related brain injury were investigated. The levels of DBZ and its hydrolyzed DSS in rat plasma and brain microdialysates were determined by liquid chromatography-mass spectroscopy/mass spectroscopy analysis. Results: We found that the mean particle size and entrapment efficacy of DBZ-PEG-NLC were similar to that of DBZ-NLC. The DBZ-PEG-NLC, like DBZ-NLC, released DBZ in a biphasic manner with initially burst release and then prolonged slow release in vitro. Intravenous injection of DBZ-PEG-NLC resulted in significantly higher levels and longer retention periods of DBZ and DSS in plasma and the brains than DBZ-NLC and DBZ in rats. Finally, treatment with DBZ-PEG-NLC achieved a better antioxidant activity than DBZ or DBZ-NLC in mouse model of ischemia/reperfusion by reducing the levels of brain malondialdehyde, but increasing the levels of brain superoxide dismutase and glutathione. Conclusion: DBZ-PEG-NLC is a preferable option to deliver DBZ for sustainable release of DSS and borneol in vivo, and may serve as a promising drug for effective therapy of ischemic cardiovascular and cerebrovascular diseases.
